Company intelligence / Profile preview
Zhongze Therapeutics
Shanghai, Shanghai, Chinazhongzetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Zhongze Therapeutics has successfully completed the first-in-human dose escalating study of ZZ6398 (SIPI6398) in healthy volunteers. Top line results indicate ZZ6398 is safe and well tolerated with better than expected PK parameters.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule drugSynthetic peptideChemical drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Digestome Therapeutics
Beyond the preview
Go deeper on Zhongze Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhongze Therapeutics.